Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

This study is currently recruiting participants.
Verified February 2013 by AIDS Community Research Initiative of America
Institute for Human Genetics and Biochemistry
Grifols Biologicals Inc.
Information provided by (Responsible Party):
AIDS Community Research Initiative of America Identifier:
First received: November 19, 2012
Last updated: February 17, 2013
Last verified: February 2013

Our primary objective is to further characterize the mechanism by which alpha-1PI regulates CD4 counts.

HIV-1 infected patients will be initiated on PROLASTIN®-C (Alpha-1 Proteinase Inhibitor [Human], Grifols Biotherapeutics Inc.) or placebo. Uninfected volunteers will be untreated and will be monitored for comparison.

Condition Intervention Phase
HIV Disease
Biological: α1 Proteinase Inhibitor
Biological: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Double Blind, Randomized Trial to Evaluate the Safety and Efficacy of 8 Weekly Doses of Prolastin®-C (α1Proteinase Inhibitor, α1PI) in Human Immunodeficiency Virus-Infected Subjects Who Are 18 to 65 Years of Age and Who Are on Antiretroviral Therapy

Resource links provided by NLM:

Further study details as provided by AIDS Community Research Initiative of America:

Primary Outcome Measures:
  • CD4 counts [ Time Frame: 9 weeks after initiation of treatment ] [ Designated as safety issue: No ]
    It has been observed that CD4 counts and cholesterol levels are correlated and that there is cyclic variation in individuals with and without HIV.

Estimated Enrollment: 20
Study Start Date: April 2012
Estimated Study Completion Date: May 2013
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: α1 Proteinase Inhibitor in HIV disease
α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks
Biological: α1 Proteinase Inhibitor
Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.
Other Names:
  • Prolastin
  • Prolastin-C
  • Zemaira
  • Glassia
Placebo Comparator: Placebo in HIV disease
Placebo (saline) weekly for 8 weeks
Biological: Placebo
No Intervention: Uninfected controls
Blood collection only for 8 weeks

  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. HIV-1 patients must have confirmed HIV-1 disease, diagnosed using the standard criteria and be on antiretroviral therapy. Uninfected volunteers will be age and gender matched.
  2. HIV-1 patients must have measurable disease, defined as HIV-1 infected patients on antiretroviral therapy with undetectable HIV RNA (<400 HIV RNA copies/ml) and CD4 counts more than 200 and less than 400 cells/uL.
  3. Not have previously received α1PI augmentation therapy
  4. Age at least 18 years and under 65 years
  5. Capacity for and commitment to attend all protocol scheduled visits at ACRIA
  6. Life expectancy of greater than 5 years
  7. Patients must have lab values within the limits defined below:

    • WBC >4,1000/uL
    • ANC >1,000/uL
    • platelets >100,000//uL
    • total bilirubin 2-12 mg/dL
    • AST(SGOT)/ALT(SGPT) < or = 2.5 X upper limit of normal
    • creatinine Male : 0.50-1.30 mg/dL Female: 0.40-1.20 mg/dL
  8. HIV-1 patients must have active α1PI below 11 uM (normal is 18-53 uM)
  9. HIV-1 patients must have one year history (prior to the study) with CD4+ lymphocytes at levels greater than 200 and less than 400 cells/uL
  10. HIV-1 patients must have absence of symptoms suggestive of HIV-1 disease progression
  11. HIV-1 patients must have adequate suppression of virus (<400 HIV RNA/mL)
  12. HIV-1 patients must have a history of compliance with antiretroviral medication based on undetectable virus levels
  13. No evidence of malignancy
  14. The effects of Prolastin-C on the developing human fetus at the recommended therapeutic dose are unknown: At any time throughout the study, from the signing of the informed consent form until after the last study visit, all female and male subjects who are biologically capable of having children must agree and commit to use a reliable method of birth control.
  15. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  1. Recent illness that will prevent the patient from participating in required study activities
  2. Patients receiving other investigational agents
  3. Patients with known malignancies
  4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Prolastin-C
  5. IgA deficient patients
  6. Patients with ≥400 HIV-1 RNA copies/ mL
  7. Patients with >400 CD4 cells/uL
  8. Uncontrolled illness including, but not limited to, ongoing or active infection, myeloid dysplastic syndrome, anemia, bone marrow failure, DiGeorge Syndrome, thymic disorders, or psychiatric illness/social situations that would limit compliance with study requirements
  9. Pregnant and breastfeeding women
  10. Refusal to give informed consent
  Contacts and Locations
Please refer to this study by its identifier: NCT01731691

Contact: Yuriy Akulov, MD, PhD 212 924 3934 ext 124
Contact: Jerry Ernst, MD 212 924 3934

United States, New York
ACRIA Recruiting
New York, New York, United States, 10018
Contact: Yuriy Akulov, MD, PhD    212-924-3934 ext 124   
Contact: Jerry Ernst, MD    (212) 924-3934   
Principal Investigator: Jerry Ernst, MD         
Sub-Investigator: Cynthia L Bristow, PhD         
Sponsors and Collaborators
AIDS Community Research Initiative of America
Institute for Human Genetics and Biochemistry
Grifols Biologicals Inc.
Principal Investigator: Jerry Ernst, MD AIDS Community Research Initiative of America
Study Director: Cynthia L Bristow, PhD Institute for Human Genetics and Biochemistry
  More Information

Additional Information:
Responsible Party: AIDS Community Research Initiative of America Identifier: NCT01731691     History of Changes
Other Study ID Numbers: Prolastin-C in HIV disease
Study First Received: November 19, 2012
Last Updated: February 17, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Alpha 1-Antitrypsin
Protease Inhibitors
Trypsin Inhibitors
Serine Proteinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions processed this record on April 17, 2014